Trials / Terminated
TerminatedNCT04456049
Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1
COVID_ENZA Trial: Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Ricardo Pereira Mestre · Academic / Other
- Sex
- Male
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
High risk outpatient adult males with a confirmed SARS-CoV-2 infection will be included in the study. Patients will be randomized to receive Enzalutamide with standard of care (SOC) or SOC alone. Enzalutamide will be administered daily p.o. from Day 1 to Day 28 or until confirmed negativization of Nasopharyngeal swap (NPS) Polymerase chain reaction (PCR) (2 consecutive negative samples), whichever occurs first.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enzalutamide | 40 mg oral tablets once daily for a maximum of 28 days. |
Timeline
- Start date
- 2020-08-24
- Primary completion
- 2021-06-09
- Completion
- 2021-06-09
- First posted
- 2020-07-02
- Last updated
- 2022-08-10
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT04456049. Inclusion in this directory is not an endorsement.